GLP-1 and GIP Obesity Drugs: Evidence

Modern obesity medicines built around GLP-1 and GIP have changed the size of weight reduction seen in randomized trials, but they have not made obesity care automatic or risk-free. A 2026 narrative review in Cureus describes semaglutide as a GLP-1 receptor agonist and tirzepatide as a dual GIP/GLP-1 receptor agonist, then places both within long-term, complication-oriented care rather than a short course aimed only at the scale^[1].

What GLP-1 and GIP drugs do

GLP-1, short for glucagon-like peptide-1, is a gut hormone involved in insulin release and appetite regulation. GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone that affects insulin secretion. Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at both the GIP and GLP-1 receptors. These are receptor targets, not a promise that every person will have the same response or tolerate treatment in the same way^[1].

That distinction is useful when reading claims about the class. A medicine with a GLP-1 label is not necessarily interchangeable with a dual agonist, and trial results cannot be lifted from one product, population, endpoint, or duration and applied to another. For the regulatory context and evidence summaries, see our pages on semaglutide and tirzepatide.

What the major obesity trials reported

In STEP 1, 1,961 adults with overweight or obesity and no diabetes were assigned to semaglutide 2.4 mg once weekly or placebo alongside lifestyle intervention for 68 weeks. Mean body-weight change was minus 14.9% with semaglutide and minus 2.4% with placebo. Nausea and diarrhea were the most common adverse events, and gastrointestinal events led to discontinuation in 4.5% of participants receiving semaglutide and 0.8% receiving placebo^[2].

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus a weight-related complication, without diabetes. At week 72, mean body-weight change was minus 15.0%, minus 19.5%, and minus 20.9% in the 5 mg, 10 mg, and 15 mg tirzepatide groups, compared with minus 3.1% with placebo. The trial reported gastrointestinal adverse events most often during dose escalation; treatment discontinuation due to adverse events ranged from 4.3% to 7.1% across active doses, versus 2.6% with placebo^[3].

Those figures show why incretin medicines have become central to obesity treatment discussions. They do not establish a universal ranking. STEP 1 and SURMOUNT-1 tested different medicines over different durations in separate trials. A direct comparison needs its own trial design, eligibility criteria, endpoint definitions, and safety reporting.

Trial averages also hide variation between participants. The published results describe what happened in the enrolled groups under protocol-defined conditions, with structured follow-up and a comparison group. They cannot predict a particular person's weight change, symptom burden, ability to remain on treatment, or the health outcome that matters most to that person.

Safety is part of the treatment question

Gastrointestinal effects are not a minor footnote in this evidence base. The Cureus review identifies nausea, vomiting, and diarrhea as the most common limitations of GLP-1 and GIP/GLP-1 receptor agonists, with symptoms most prominent during dose escalation^[1]. The two large trials also reported gastrointestinal events and some discontinuations for that reason^[2][3].

That is why a headline weight-loss percentage is not enough for an individual decision. A prescribing clinician can assess medical history, current medicines, contraindications, adverse effects, and whether the expected benefit matches the complications being treated. This article does not recommend a medicine, a dose, or a route to obtain one.

Why longer-term care still matters

The review behind this article argues for moving beyond weight alone and considering metabolic, cardiovascular, liver, kidney, and quality-of-life outcomes in long-term care^[1]. That framing is sensible because a percentage change on a study endpoint does not answer every practical question: whether weight loss is maintained, how adverse effects affect daily life, what happens after treatment changes, or which outcomes matter most for a particular person.

It also keeps the scope honest. Semaglutide and tirzepatide have substantial randomized-trial evidence in obesity, while the review lists newer candidates such as retatrutide, CagriSema, MariTide, and amycretin as emerging options with limited long-term efficacy and safety data^[1]. A development program is not the same thing as an approved treatment, and early results should not be treated as a substitute for completed evidence or regulatory review.

What we do not yet know

The published trials provide strong evidence that these medicines can reduce average body weight under trial conditions. They do not settle every long-term question for every population. The 2026 review itself notes that long-term efficacy and safety data for emerging multi-receptor and combination therapies remain limited^[1]. Readers should be cautious with claims that turn a class result, a company announcement, or a single early study into a settled answer about lifelong treatment.

What this means for readers

The useful takeaway is narrower than the hype. GLP-1 and dual GIP/GLP-1 medicines have produced large average weight reductions in major randomized trials, and gastrointestinal tolerability is a real part of the trade-off. If you are considering treatment, use a qualified healthcare professional to discuss the approved options in your jurisdiction and the evidence that applies to your health situation.